CVD-1208S122 is under clinical development by Emergent BioSolutions and currently in Phase I for Bacillary Dysentery (Shigellosis). According to GlobalData, Phase I drugs for Bacillary Dysentery (Shigellosis) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CVD-1208S122 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CVD-1208S122 is under development for the prevention of bacillary dysentery (shigellosis). . It is administered by oral route and is a recombinant vector vaccine expressing enterotoxigenic Escherichia coli (ETEC) antigens.
It was also under development for the treatment of traveler's diarrhea.
Emergent BioSolutions overview
Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious diseases and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent’s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
For a complete picture of CVD-1208S122’s drug-specific PTSR and LoA scores, buy the report here.